Strategy Design Service for NASH Combination Therapies

Creative Biolabs is a global company that focuses on NASH treatment development. With our extensive experience and advanced platform, we can provide a series of services on NASH combination therapies basing on a wide variety of state-of-art technologies. We are dedicating to assisting our clients with the most satisfactory data to meet any requirement of your projects.

Introduction to Combination Therapies

Combination therapy is a strategy that combines multiplex agents for particular disease treatment. In recent years, combination therapy has shown its safety and efficacy in treating a wide variety of diseases, such as tuberculosis (TB), nonalcoholic steatohepatitis (NASH) and various types of cancers. Meanwhile, pilot studies have demonstrated that combination therapy overcomes the limitations of traditional monotherapy by selectively targeting the abnormal proliferation of cells and disease pathogenesis. In general, traditional monotherapy may lead to a range of side effects and toxicities in patients. However, the combination therapy can largely reduce the toxicity because the multiple pathways will be selected for disease therapy. Furthermore, more recent research has illustrated that combination therapy plays an essential role in preventing the cytotoxic effects on disease-related cells. If one drug is antagonistic to another drug in normal cells, it may protect normal cells from cytotoxic effects in patients’ combination therapy. In a word, combination therapy is a synergistic or additive method for the treatment of numerous diseases, so the dosage of each agent and the safety profiling are needed to be identified.

Fig.1 Histologic features of human NASH. (Cohen, 2011)

Our Platform for Combination Therapies

In Creative Biolabs, combination therapy has been widely used in NASH therapy and we have successfully accomplished a panel of assays to determine optimal combinations and dosages. Moreover, we have developed a comprehensive platform for revealing the mechanism and critical drivers of NASH. We can offer a series of services on understanding and discovering the potential pathogenic targets in a single combination. In this platform, big data approaches and gene expression detection are the common assays for defining new targets for NASH treatment. Additionally, the transcription pathways affected by one drug will be constantly monitored, and other drugs will be tested and validated for further capturing the new pathogenic drivers basing on in vitro approaches. As a result, we have established a wide array of advanced techniques to uncover the target molecules, including but not limited to, animal modeling, histologic analysis and polymerase chain reaction (PCR).

Fig.2 Key targets for drugs in phase 2 and phase 3 clinical trials. (Connolly, 2018)

Creative Biolabs is recognized as the world leader for providing the most diverse portfolio of NASH-associated target discovery solutions for worldwide customers. We are proud to partner with our clients on the journey of bringing novel candidate targets to market. If you are interested in our services, please feel free to contact us for closer communication to learn how we can be involved in your project. Separate services or integrated end-to-end solutions are all welcomed.

References

1. Cohen, J.C.; et al. Human fatty liver disease: old questions and new insights. Science. 2011, 332(6037): 1519-1523.
2. Connolly, J.J.; et al. Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials. J Clin Transl Hepatol. 2018, 6(3): 264-275.